Secondary analysis of the CLL12 trial (515 patients with early-stage CLL): ibrutinib vs placebo improved event-free survival in several genetic subgroups but not with del(17p) or TP53 mutations, and gave no overall survival benefit in any subgroup (median follow-up 69.3 months).
Secondary analysisn = 515
Riecke et al. Ibrutinib for early-stage CLL: genetic risk factors and treatment outcome in the GCLLSG CLL12 trial